Similarly, CD161 interacts with its receptor LLT1 to regulate the oral squamous cell carcinoma (OSCC) tumor immune microenvironment, thereby improving the prognosis of OSCC patients (Hu et al., 2024). Here, CLEC2D is linked to neoplasm.